Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Part of paid clinical trials in Jacksonville, Florida.

Sponsor: East Coast Institute for Research
Study ID: NCT06865144
Phase: PHASE4
Status: Active Not Recruiting

Conditions

Primary Open Angle Glaucoma or Ocular Hypertension

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Netarsudil ophthalmic solution 0.02% — DRUG
Apply one drop in each eye every evening
Artificial tears — DRUG
Apply one drop in each eye every evening

Study Details

The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.

Key Dates

Start date: Jun 27, 2025
Status verified: Jun 2026
Primary completion: Jul 31, 2026
Completion: Sep 1, 2026

Study Design

Enrollment: 70 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Rhopressa
Placebo Comparator: Artificial Tears

Primary Outcome Measure

Mean diurnal intraocular pressure (IOP) [ Time Frame: 42 Days ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
East Coast Institute for Research at Florida Eye Specialists	Jacksonville	Florida	32256	-

Find similar trials in Jacksonville, FL

By research site

East Coast Institute for Research at Florida Eye Specialists· Jacksonville, FL

Related Studies

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
Recruiting · Brian Shafer · Plymouth Meeting, Pennsylvania